PAVING A NEW PATH FOR TREATING CANCER

Committed to developing innovative cancer therapies, Dendreon is evaluating a variety of therapeutic approaches. While each of these approaches uses distinct mechanisms of action to destroy cancer cells, they all share a common attribute—the potential to be a targeted therapy that addresses an unmet medical need, improves the lives of patients and has favorable safety and tolerability profiles.

Dendreon is developing active cellular immunotherapies, small molecules and monoclonal antibodies for a variety of cancers.

Dendreon protects its technology through numerous United States and foreign patent filings, trademarks and trade secrets that it owns or licenses. The Company has issued patents or patent applications that are directed to the solutions and devices by which cells can be isolated and manipulated, its Antigen Delivery Cassette™, antigen-presenting cell processing, and its monoclonal antibody and small molecule product candidates.